Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT03724851 | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | completed | Phase 1 / Phase 2 | 120 | MedPacto, Inc.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT05267470 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)(FORTITUDE-201) | terminated | Phase 1 | 74 | AmgenINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT03046992 | Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC | completed | Phase 1 / Phase 2 | 224 | Yuhan CorporationINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01518556 | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia(IDAML) | completed | Phase 1 / Phase 2 | 49 | Konkuk University Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 95 | MacroGenicsINDUSTRY | 5 | Mar 17, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT05514496 | A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer | active not recruiting | Phase 1 | 258 | Nalo Therapeutics Inc.INDUSTRY | 3 | Mar 11, 2025 | clinicaltrials |
| NCT03579836 | Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 75 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05093907 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 27 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT01148849 | Safety Study of MGAH22 in HER2-positive Carcinomas | completed | Phase 1 | 66 | MacroGenicsINDUSTRY | 2 | Feb 26, 2025 | clinicaltrials |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | terminated | Phase 1 / Phase 2 | 7 | Dawonmedax Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05943041 | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | completed | Phase 1 | 9 | GILongevityINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06293651 | Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02187848 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 254 | SanofiINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | terminated | Phase 1 | 13 | Biomea Fusion Inc.INDUSTRY | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05749900 | First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) | recruiting | Phase 1 / Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT03821233 | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | completed | Phase 1 | 112 | Zymeworks BC Inc.INDUSTRY | 4 | Jan 29, 2025 | clinicaltrials |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | terminated | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Jan 28, 2025 | clinicaltrials |
| NCT04662112 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma(NASOX) | completed | Phase 1 / Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04492033 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | terminated | Phase 1 / Phase 2 | 41 | Handok Inc.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT01084863 | Evaluate Safety, Efficacy and Pharmacokinetics(Compare) | completed | Phase 1 / Phase 2 | 143 | CelltrionINDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT01121588 | Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) | terminated | Phase 1 | 44 | PfizerINDUSTRY | 7 | Jan 23, 2025 | clinicaltrials |
| NCT04074759 | FPT155 in Patients With Advanced Solid Tumors(FPT155-001) | terminated | Phase 1 | 80 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT03936959 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | terminated | Phase 1 | 10 | Eli Lilly and CompanyINDUSTRY | 5 | Jan 15, 2025 | clinicaltrials |
| NCT03509012 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors(CLOVER) | completed | Phase 1 | 105 | AstraZenecaINDUSTRY | 5 | Jan 14, 2025 | clinicaltrials |
| NCT06012708 | Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 | completed | Phase 1 | 12 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT04594005 | CDK4/6 Tumor, Abemaciclib, Paclitaxel | completed | Phase 1 / Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT05162274 | Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers. | completed | Phase 1 | 38 | Yuhan CorporationINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03698825 | TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer | completed | Phase 1 / Phase 2 | 62 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials